KRT88P and chronic hepatitis B virus infection: In conclusion, Canocapavir demonstrates a robust antiviral activity and is a chemically and mechanistically unique type of capsid assembly modulator, thus representing a promising antiviral agent for treatment of chronic hepatitis B. Of particular note, our work strongly suggests the allosteric effect induced by Canocapavir treatment on HBc not only promotes the formation of capsid and disrupts the pgRNA encapsidation, but also reduces the capsid envelopment and secretion.